Targeting apoptosis pathways in cancer therapy.
Killing of tumor cells by anticancer therapies commonly used in the treatment of cancer, e.g. chemotherapy, gamma-irradiation, immunotherapy or suicide gene therapy, is predominantly mediated by triggering apoptosis, the cell's intrinsic death program. Accordingly, defects in apoptosis pathways can result in cancer resistance to current treatment approaches. Understanding the molecular mechanisms that regulate cell death programs including apoptosis, and how resistant forms of cancer evade apoptotic events, may provide novel opportunities for cancer drug development.
Fulda
Simone
S
University Children's Hospital, Prittwitzstr. 43, 89075 Ulm, Germany.
Debatin
Klaus-Michael
KM
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology
D000970:Antineoplastic Agents